FDA likely to relent on UniQure's Huntington's drug
Andy Summers argued that despite a recent regulatory setback, the FDA will likely relent and allow UniQure to use a historical control group for its Huntington's disease drug AMT-130 due to immense unmet need and community pressure.
Sign in to read the full idea
The argument, what validates it, the risks discussed and hearing it from the source are for signed-in members. Free accounts read 3 ideas in full a day. No card required.